TAK1/MAP4K2 inhibitor 1 is a potent dual inhibitor of TGFβ-activated kinase 1 (TAK1) and MAP4K2 (IC50s: 41.1 nM and 18.2 nM).

GNE-1858 is an ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA).

MAP4K4-IN-3 (Compound 17) may be a viable target for antidiabetic agents, a serine/threonine protein kinase.

TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in human hepatic stellate cell LX-2. This compound is applicable in the inhibition of cancer and fibrosis [1].

PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.

GNE-495 is a potent and specific MAP4K4 inhibitor (IC50: 3.7 nM).

KY-05009 is a chemical compound that effectively suppresses TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells, reduces TNIK protein expression and the transcriptional activity of Wnt target genes, and promotes apoptosis in cancer cells, displaying anti-cancer properties. Furthermore, it functions as an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM.

HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.

DMX-5804 is a potent, selective MAP4K4 inhibitor, with an IC50 of 3 nM.DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.

NCB-0846 is an orally active TNIK inhibitor (IC50: 21 nM).

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.

HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).

HPK1-IN-10 is a potent inhibitor of HPK1, a serine/threonine protein kinase cloned from hematopoietic progenitor cells and a member of the MAP4K family of mammalian Ste-20-associated protein kinases. HPK1-IN-10 has potential for HPK1-related diseases.

HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.

HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.

HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.

HPK1-IN-18 is a highly effective and specific HPK1 inhibitor. HPK1, a MAP kinase kinase kinase kinases (MAP4K) member, was initially isolated from hematopoietic progenitor cells. This compound, known as HPK1-IN-18, is valuable for investigating, preventing, or managing diseases or conditions linked to HPK1 activity, such as cancer[1].

HPK1-IN-9 is a potent HPK1 inhibitor. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and is a member of the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has potential for HPK1-related diseases.